NASDAQ:ARVN Arvinas Q3 2025 Earnings Report $9.21 +0.05 (+0.55%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$9.32 +0.11 (+1.19%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Arvinas EPS ResultsActual EPSN/AConsensus EPS -$0.74Beat/MissN/AOne Year Ago EPSN/AArvinas Revenue ResultsActual RevenueN/AExpected Revenue$29.36 millionBeat/MissN/AYoY Revenue GrowthN/AArvinas Announcement DetailsQuarterQ3 2025Date10/29/2025TimeBefore Market OpensConference Call DateWednesday, October 29, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Arvinas Earnings HeadlinesArvinas presents preclinical data for ARV-806October 24 at 12:01 AM | msn.comArvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International ...October 24 at 7:01 PM | markets.businessinsider.comOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.October 25 at 2:00 AM | Banyan Hill Publishing (Ad)Arvinas Unveils Promising Preclinical Data for ARV-806October 24 at 4:51 PM | tipranks.comArvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 24 at 4:00 PM | globenewswire.comArvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from AnalystsOctober 23 at 2:48 AM | americanbankingnews.comSee More Arvinas Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email. Email Address About ArvinasArvinas (NASDAQ:ARVN) (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems. The company’s most advanced clinical candidates address hormone-driven cancers. ARV-110 (bavdegalutamide) is being evaluated for the treatment of metastatic castration-resistant prostate cancer, while ARV-471 (voredabolu) is in development for ER+/HER2- breast cancer. Both programs have shown favorable pharmacokinetic profiles in early-phase trials and reflect Arvinas’s strategy of advancing a focused pipeline of next-generation small molecules designed to degrade pathogenic proteins. Since its founding in 2013 and incorporation in New Haven, Connecticut, Arvinas has established collaborative partnerships with leading pharmaceutical companies to expand the reach of its PROTAC platform. Agreements with Pfizer and Roche, among others, provide access to complementary expertise in oncology and other therapeutic areas. The company conducts research and development in the United States and maintains relationships with regulatory authorities in North America and Europe as it pursues global clinical development. Arvinas is led by President and Chief Executive Officer Robert A. Ross, who joined the company in 2022 following a tenure at a major pharmaceutical association. Under his leadership, the company continues to advance its pipeline while building a broader platform for targeted protein degradation. Arvinas remains committed to translating its scientific innovations into transformative therapies for patients with unmet medical needs. View Arvinas ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)American Tower (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.